Summary of Accomplishments As of 1/21/16
|
|
- Arline Willis
- 7 years ago
- Views:
Transcription
1 Summary of Accomplishments As of 1/21/16 VALUE TO THE HCT COMMUNITY The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) plays a critical role in improving patient outcomes and advancing the science of hematopoietic stem cell transplantation (HCT). The Network s many achievements include: Launching 38 trials, including 5 led by National Cancer Institute (NCI) Cooperative Groups Completing accrual to 28 trials Completing follow-up to primary endpoint for 20 of the 23 BMT CTN-led studies Accruing >8,600 patients from >125 centers o Accruing >400 patients with rare diseases: sickle cell disease, severe aplastic anemia, hemophagocytic syndromes, and primary immune deficiencies Having an overall accrual rate that is approximately 150% of projections among trials that are currently open for enrollment Establishing a research repository that currently includes >350,000 biospecimens Engaging in 48 ancillary and correlative studies Presenting 59 abstracts Publishing 57 manuscripts, including 16 of primary results BMT CTN Annual and Cumulative Accrual to All Protocols SIGNIFICANCE Approximately 21,000 HCTs are performed in the US annually, and the number increases by about 2% per year. HCT is a rapidly evolving field, and HCT clinical trials face unique challenges, including the relatively small number of transplantations performed at any single center, the diverse indications for HCT, the complexities of the intervention, and multiple posttransplant complications. The BMT CTN was established in 2001 to address these challenges and execute multicenter HCT trials with broad national participation. The Network studies various treatment options and answers research questions relevant to both common and rare diseases. RESOURCEFUL Support from industry partners (including in-kind contributions) and other grants has increased the effective investment from NIH by an estimated $370 million EFFICIENT Median time from protocol team formation to protocol release is currently 14.7 months Median time from date of evaluable data to manuscript submission is 8.7 months PRODUCTIVE Primary manuscripts pending for only 3 trials of 20 trials reaching primary endpoint 21 publications of ancillary studies evaluating the biology of HCT and impact on patients
2 SIGNIFICANT FINDINGS AND IMPACT The research findings of the BMT CTN provide information with relevance for clinical practice. Network trials have provided important insights into several areas of HCT. Significant Findings and Impact of Published BMT CTN Studies BMT CTN Study Results Impact / Future Outlook UNDER-REPRESENTED POPULATIONS 0502 (CALGB ): Phase II study of allogeneic transplant for older patients with acute myeloid leukemia (AML) in first morphologic complete remission using a nonmyeloablative preparative regimen 0601: Unrelated donor hematopoietic cell transplantation for children with severe sickle cell disease using a reducedintensity regimen 0803 (AMC-071): High dose chemotherapy with autologous stem cell rescue for aggressive B cell lymphoma and Hodgkin lymphoma in human immunodeficiency virus (HIV)-infected patients Demonstrated the feasibility and effectiveness of allogeneic transplant using reducedintensity in this first prospective US cooperative group trial conducted in a homogeneously treated group of older AML patients in first remission Determined that a reducedintensity regimen of alemtuzumab, fludarabine, and melphalan, followed by bone marrow HCT resulted in low rates of regimenrelated organ toxicity and a one year event-free survival of 76% Initially found that this regimen, although effective for engraftment of bone marrow, was associated with unacceptably high levels of graft failure after cord blood transplantation; this led to the closure of the cord blood cohort Determined that patients with HIV-associated lymphoma may successfully undergo autologous transplant with favorable outcomes This protocol was a collaborative effort between the BMT CTN and Cancer and Leukemia Group B (CALGB). CALGB accrual began in 2006, but enrollment was low; BMT CTN activated the study, and the trial rapidly met its original accrual goal. The study demonstrates that, with reducedintensity, patients older than 60 can benefit from the graft-versus-leukemia effects of allogeneic HCT with outcomes similar to younger patients. These data should increase the use of HCT in older AML patients and provides justification for BMT CTN allograft trials. This finding confirmed that using a reducedintensity regimen followed by bone marrow HCT results in acceptable rates of engraftment and survival but high risks of chronic GVHD, underscoring the need for future trials on effective GVHD prophylaxis. Additionally, early on in the study, there was a disappointing finding that using cord blood as a stem cell source resulted in unacceptably high levels of graft failure, which indicates the need for novel transplant strategies for the large number of sickle cell disease patients who cannot find an HLA-matched adult donor. Two additional BMT CTN sickle cell transplant trials are currently in development. One compares HLA-matched bone marrow HCT to standard of care (BMT CTN 1503), and the other uses haplo-identical donors (BMT CTN 1507). The BMT CTN conducted this study in collaboration with the AIDS Malignancy Consortium (AMC) in an effort to assess whether autologous HCT is a viable therapeutic option for a patient population frequently excluded from HCT clinical trials. Based on the study findings, autologous transplant should be considered the standard of care for patients with relapsed / refractory HIV-associated lymphoma who meet standard eligibility criteria. The BMT CTN and AMC are also evaluating the use of allogeneic HCT for HIV-infected patients with hematological cancers and myelodysplastic syndrome in the newly-completed BMT CTN 0903 trial.
3 Significant Findings and Impact of Published BMT CTN Studies BMT CTN Study Results Impact / Future Outlook GRAFT SOURCES 0501: Multicenter, open label, randomized trial comparing single versus double umbilical cord blood transplantation in pediatric patients with leukemia and myelodysplasia 0201: A Phase III randomized, multicenter trial comparing G-CSF mobilized peripheral blood stem cell with marrow transplantation from HLA compatible unrelated donors 0603/0604: Multicenter, Phase II trials of nonmyeloablative and transplantation of partially HLA-mismatched bone marrow / umbilical cord blood from unrelated donors in patients with hematologic malignancies Demonstrated no survival benefit and more acute GVHD for children receiving infusion of two umbilical cord blood units versus one umbilical cord blood unit after transplantation for hematologic malignancies Found no difference in survival for recipients of unrelated donor peripheral blood versus bone marrow grafts, but an increased risk of chronic GVHD requiring prolonged immune suppression with peripheral blood grafts Confirmed single-center results in a multicenter setting using reduced-intensity and haploidentical bone marrow transplantation or double cord blood transplantation in adults with hematologic malignancies, with data supporting a subsequent Phase III trial This study indicates, unexpectedly, that increasing cell dose beyond the accepted minimum by adding another cord blood unit does not improve survival after cord blood transplantation in children and increases the risk of acute GVHD. This has important implications for future strategies to improve hematopoietic recovery and decrease transplant-related mortality after cord blood HCT. Peripheral blood has largely replaced bone marrow as a graft source for unrelated donor transplantation. This study suggests this may not be appropriate in the myeloablative setting. This is the largest prospective study of unrelated donor transplantation ever performed. It would not have been possible without the infrastructure provided by the BMT CTN. Acceptable outcomes of double cord and haploidentical bone marrow transplantation suggest that many more adults should be offered HCT, even when an HLA-matched adult donor is not available. These approaches are now being compared in a randomized Phase III trial (BMT CTN 1101). CONDITIONING REGIMENS AND INTENSITY 0301: Fludarabine-based for allogeneic marrow transplantation from human leukocyte antigen (HLA)-compatible unrelated donors in severe aplastic anemia Identified the optimal dose of cyclophosphamide for unrelated donor HCT in severe aplastic anemia is less than 150 mg/kg Optimizing transplantation regimens for rare diseases is difficult and requires a multicenter effort. This study determined that fludarabine is not sufficiently immune suppressive to replace cyclophosphamide in regimens for unrelated donor transplantation for aplastic anemia. Additionally, it found excess toxicity with a commonly used dose of cyclophosphamide when combined with fludarabine. This unexpected finding is anticipated to change practice in many centers. A follow-up study for aplastic anemia patients is in development (BMT CTN 1502) using the optimal cyclophosphamide dose found in this study. Additionally, the upcoming study will incorporate cord blood and haplo-identical donors to reach patients who are not able to find an unrelated donor.
4 Significant Findings and Impact of Published BMT CTN Studies BMT CTN Study Results Impact / Future Outlook 0901: Phase III allogeneic HCT comparing regimen intensity in patients with myelodysplastic syndrome or acute myeloid leukemia Found that reduced-intensity results in higher relapse rates and lower treatment-related mortality compared to myeloablative The data from this trial support myeloablative as the standard of care for patients who are able to receive it. For patients who are not candidates for myeloablative, novel regimens, which incorporate enhanced anti-leukemia activity without increasing toxicity, are needed. One such regimen of maintenance therapy post-hct for FLT3- positive AML patients is in development (BMT CTN 1506). GRAFT-VERSUS-HOST DISEASE PREVENTION AND TREATMENT 0303: A single-arm, multicenter Phase II trial of transplants of HLAmatched, CD34+ enriched, T cell depleted peripheral blood stem cells isolated by the CliniMACS system in the treatment of patients with AML in first or second complete remission Confirmed, in a multicenter setting, the feasibility and consistency of T cell depletion by CD34 selection, with results in AML that warranted development of a phase III trial versus non-t cell depleted transplantation These data were used by the Food and Drug Administration in its determination to approve, for the first time, a CD-34 selection column for clinical use in the US. A Phase III trial comparing outcomes of CD34-selected transplants using this approach with standard bone marrow transplants followed by calcineurin-inhibitor based GVHD prophylaxis (BMT CTN 1301 PROGRESS II) is open in the BMT CTN. 0402: A Phase III randomized, multicenter trial comparing sirolimus / tacrolimus with tacrolimus / methotrexate as GVHD prophylaxis after HLAmatched, related peripheral blood stem cell transplantation 0802: Randomized, double blind, Phase III trial evaluating corticosteroids with MMF vs. corticosteroids with placebo as initial systemic treatment of acute GVHD Identified a high risk of toxicity when sirolimus is substituted for standard methotrexate for GVHD prophylaxis when the regimen includes busulfan and no advantage in acute GVHD-free survival Found no GVHD-free survival benefit with the addition of MMF In an important ancillary study, determined that GVHD biomarker panels can be used for early identification of patients at high or low risk for treatment non-responsiveness or death and that biomarker panels may provide opportunities for early intervention and improved survival following HCT Although this study showed a modest improvement in grade III-IV acute GVHD, the findings do not support substituting sirolimus for methotrexate since it may increase toxicity in patients who receive busulfan for, it was associated with higher risks of chronic GVHD, and it did not improve survival. Novel approaches to preventing GVHD are needed and are being explored in the recently opened BMT CTN 1203 PROGRESS I and 1301 PROGRESS II studies. Although the 0802 results were discouraging, the BMT CTN has used these studies to focus on a newer therapeutic agent, sirolimus, in the upcoming BMT CTN 1501 study using a biomarker risk stratification developed in BMT CTN 0302 and The Network s ability to conduct GVHD studies in timely manner allows for definitive Phase III results to be quickly disseminated and promising agents to be efficiently tested in new studies.
5 PRIMARY RESULTS PUBLICATIONS Devine et al. A Phase II study of allogeneic transplantation for older patients with AML in first complete remission using a reduced intensity regimen: results from CALGB (Alliance) / BMT CTN Journal of Clinical Oncology Dec 10; 33(35): Epub 2015 Nov 2. Anderlini et al. Cyclophosphamide in patients with severe aplastic anemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study. Lancet Haematology Sep 1; 2:e Wagner et al. One- vs two-unit cord blood transplant for leukemia. New England Journal of Medicine Oct 30; 371(18): Bolaños-Meade et al. Phase III clinical trial steroids / mycophenolate mofetil vs steroids / placebo as therapy for acute GVHD: BMT CTN Blood Nov 20; 124(22): Epub 2014 Aug 28. Cutler et al. Tacrolimus / sirolimus vs tacrolimus / methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood Aug 21; 124(8): Epub 2014 Jun 30. Jacobsen et al. Exercise and stress management training prior to HCT: BMT CTN Biology of Blood and Marrow Transplantation Oct 1; 20(10): Epub 2014 Jun 6. Yanik et al. A randomized double-blind, placebocontrolled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome following allogeneic HCT. A BMT CTN protocol. Biology of Blood and Marrow Transplantation Jun 1; 20(6): Epub 2014 Mar 11. Vose et al. Phase III Randomized study of BEAM compared with 131-iodine tositumomab / BEAM with autologous HCT for relapsed diffuse large B-cell lymphoma: Results from the BMT CTN 0401 Trial. Journal of Clinical Oncology May 1; 31(13): Epub 2013 Mar 11. Anasetti et al. PBSC versus bone marrow from unrelated donors. New England Journal of Medicine Oct 18; 367(16): McCarthy et al. Lenalidomide after HCT for multiple myeloma. New England Journal of Medicine May 10; 366(19): Krishnan et al. Autologous HCT followed by allogeneic or autologous HCT in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncology Dec; 12(13): Epub 2011 Sep 29. Brunstein et al. Alternative donor transplantation: results of parallel phase II trials using HLA-mismatched related bone marrow or unrelated umbilical cord blood grafts. Blood Jul 14; 118(2): Epub 2011 Apr 28. Devine et al. Low risk of chronic GVHD and relapse associated with T cell depleted peripheral blood stem cell transplantation for AML in first remission: results of the BMT CTN Protocol Sep; 17(9): Epub 2011 Feb 12. Tomblyn et al. Autologous vs reduced intensity allogeneic HCT for patients with chemosensitive follicular non-hodgkin lymphoma beyond first complete response or first partial response Jul; 17(7): Epub 2010 Nov 10. Wingard et al. Randomized double-blind trial of fluconazole vs voriconazole for prevention of invasive fungal infection after allogeneic HCT. Blood Dec 9; 116(24): Epub 2010 Sep 8. Alousi et al. Etanercept, mycophenolate, denileukin or pentostatin plus corticosteroids for acute GVHD, a randomized phase II trial from the BMT CTN. Blood Jul 1; 114(3): Epub 2009 May 14. OTHER RECENT PUBLICATIONS Young et al. Infections after transplantation of bone marrow or PBSC from unrelated donors Feb 1; 22(2): Epub 2015 Sep 25. Wood et al. Patient-reported physical functioning predicts success of HCT (BMT CTN 0902). Cancer Jan 1; 122(1): Epub 2015 Oct 6. Khera et al. Comparison of characteristics and outcomes of trial participants and nonparticipants: example of BMT CTN 0201 trial Oct 1; 21(10):
6 SPONSORSHIP The BMT CTN is funded by two Institutes at the NIH: The National Heart, Lung, and Blood Institute and The National Cancer Institute. COLLABORATION The BMT CTN is a network of HCT centers that work together to achieve common goals. In addition to the Network s core centers, the BMT CTN encourages and facilitates broad participation of the HCT community through its Affiliate Center system. More than 100 Affiliate Centers enroll patients on Network trials, and about 20% of the BMT CTN s overall accrual comes from Affiliate Centers. Furthermore, the Network collaborates with a variety of partners, including: NIH Institutes: Other Contributions National Heart, Lung and Blood Institute additional R01 support National Institute of Allergy and Infectious Diseases National Institute on Minority Health and Health Disparities NIH-Funded Networks / Consortia AIDS Malignancy Consortium Alliance for Clinical Trials in Oncology Children s Oncology Group Eastern Cooperative Oncology Group NCI National Clinical Trials Network Office of Rare Diseases Research Sickle Cell Disease Clinical Research Network SWOG Industry Partners AMGEN The Binding Site, Inc. Celgene Corporation GlaxoSmithKline Millennium The Takeda Oncology Company Miltenyi Biotec GmbH Roche Wyeth Pharmaceuticals Inc. CIBMTR 9200 W Wisconsin Ave, Ste C5500 Milwaukee, WI Ph: cibmtr.org The Emmes Corporation 401 N Washington St, Ste 700 Rockville, MD Ph: emmes.com bmtctn.net BMT CTN CORE CENTERS The 20 core centers are listed to the right; consortia are noted with an asterisk. Baylor College of Medicine* o Children s National Medical Center Case Western Reserve University* o Cleveland Clinic o Oregon Health & Science University o West Virginia University City of Hope Dana Farber Cancer Institute / Brigham & Women s Hospital* o Massachusetts General Hospital o Boston Children's Hospital Duke University Fred Hutchinson Cancer Research Center H. Lee Moffitt Cancer Center Johns Hopkins University Memorial Sloan-Kettering Cancer Center Northside Hospital Ohio State University* o Roswell Park Cancer Institute o UCSF Medical Center o University of North Carolina Hospitals o Virginia Commonwealth University Pediatric Blood and Marrow Transplant Consortia o >100 pediatric programs Stanford Hospitals and Clinics University of Florida* o Emory University University of Michigan* o Mayo Clinic, Minnesota o Mount Sinai Medical Center o Vanderbilt University University of Minnesota University of Nebraska* o University of Kansas University of Pennsylvania University of Texas, MD Anderson Cancer Center Washington University Medical School The Data and Coordinating Center is a collaborative partnership of three organizations: NMDP/Be The Match 500 North 5 th Street Minneapolis, MN Ph: bethematch.org
Hematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine
Hematopoietic Stem Cell Transplantation Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cells Harvested from blood, bone marrow, umbilical cord blood Positive selection of CD34 (+) cells
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll
More informationCHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION
CHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION Chapter 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION 1.1 OVERVIEW OF THE CORD BLOOD TRANSPLANTATION STUDY Bone marrow transplantation
More informationBone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Bone Marrow Transplantation
More informationBlood-Forming Stem Cell Transplants
Blood-Forming Stem Cell Transplants What are bone marrow and hematopoietic stem cells? Bone marrow is the soft, sponge-like material found inside bones. It contains immature cells known as hematopoietic
More informationPr Eliane Gluckman, MD, FRCP, Disclosure of Interest: Nothing to Disclose
Pr Eliane Gluckman, MD, FRCP, Hospital Saint Louis, University Paris- Diderot, France Should Haplo-identical transplantation be preferred to cord blood in patients without a matched donor? Disclosure of
More informationDisclosures. I have no disclosures.
Not Your Own Marrow Jenni Krajewski, MD Clinical Assistant Professor, Rutgers New Jersey Medical School Attending Physician, Pediatric Blood and Marrow Transplantation The Institute for Pediatric Cancer
More informationStem Cell Transplantation In Patients with Fanconi Anemia
Stem Cell Transplantation In Patients with Fanconi Anemia FARF Annual Family Meeting 6/28/15 Casco, ME Parinda A. Mehta, M.D. Cincinnati Children s Hospital Medical Center Improvements in Unrelated Donor
More informationHematopoietic Stem Cell Transplantation: Evolving Strategies That Have Resulted in Improved Outcomes
Hematopoietic Stem Cell Transplantation: Evolving Strategies That Have Resulted in Improved Outcomes Asad Bashey, MD, PhD Blood and Marrow Transplantation Program at Northside Hospital Atlanta, Georgia
More informationinformation for payers and referrers
a d u lt s t e m c e l l t r a n s p l a n tat i o n p r o g r a m information for payers and referrers Spring 2014 For more information, visit www.dfbwcc.org/bmt. o u r expertise Since its founding in
More informationNarrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood
[Track 2: What Is a Transplant?] Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood can be an effective treatment for people with blood cancers such as leukemia,
More informationSelection of the Optimal Umbilical Cord Blood Unit
Karen Ballen, MD Selection of the Optimal Umbilical Cord Blood Unit Massachusetts General Hospital September, 2013 OUTLINE Cell Dose HLA Match Allele Level HLA C KIR Directional Mismatch NIMA HLA Antibodies
More informationStem Cell Transplantation
Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance
More informationCord Blood Stem Cell Transplantation
LEUKEMIA LYMPHOMA MYELOMA FACTS Cord Blood Stem Cell Transplantation No. 2 in a series providing the latest information on blood cancers Highlights Umbilical cord blood, like bone marrow and peripheral
More informationHematopoietic Stem Cell Transplantation: Current Status and Future Directions RICHARD W. CHILDS M.D. NIH, BETHESDA MD
Hematopoietic Stem Cell Transplantation: Current Status and Future Directions RICHARD W. CHILDS M.D. NIH, BETHESDA MD Stem cell transplantation Autologous Autologous stem cell collection Freeze Stem Cells
More informationCord Cor Blood Banking Scott N. Furlan, MD Ellen S. Plummer, Plummer MD
Cord Blood Banking Scott N. Furlan, MD Ellen S.Plummer, MD Overview Background Biology of Stem Cell Transplant Opportunities i at Parkland Logistics of Banking Potential Barriers Indications for HCT Cancer
More informationFetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant. Recipients
Fetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant Recipients Filippo Milano, 1 J. Lee Nelson, 1, 2 Colleen Delaney 1,3 1 Clinical Research Division, Fred Hutchinson Cancer Research
More informationPros and Cons of Stem Cell Sources and their availability in Africa. Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa
Pros and Cons of Stem Cell Sources and their availability in Africa Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa Introduction The ability to perform a haematopoietic stem
More informationDEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT
www.narayanahealth.org DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT About Narayana Health City Narayana Health, one of India's largest and the world's most economical healthcare service providers
More informationInfosheet. Allogeneic stem cell transplantation in myeloma. What is the principle behind stem cell transplantation?
Infosheet Allogeneic stem cell transplantation in myeloma High-dose therapy and autologous stem cell transplantation is currently the first-line treatment standard of care for younger/fitter myeloma patients.
More informationCord Blood: Research Progress and Future Promise
Cord Blood: Research Progress and Future Promise By Al Staropoli, AABB Contributing Writer Sue Fister found out she had leukemia when she was 50 years old. Doctors suggested a bone marrow transplant as
More informationBLOOD AND MARROW TRANSPLANT PROGRAM
BLOOD AND MARROW TRANSPLANT PROGRAM We offer a team approach to patient care that centers around our patients and their caregivers; we focus on providing comprehensive, holistic care for the best possible
More informationCorporate Medical Policy Cord Blood as a Source of Stem Cells
Corporate Medical Policy Cord Blood as a Source of Stem Cells File Name: Origination: Last CAP Review: Next CAP Review: Last Review cord_blood_as_a_source_of_stem_cells 2/2001 3/2015 3/2016 3/2015 Description
More informationBone Marrow/Stem Cell Transplant
Blue Distinction Centers for Transplants Program Selection Criteria for 2010 Mid-Point Designations To qualify as a Blue Distinction Center for Transplants (), each facility must satisfy s quality based
More informationMEDICAL COVERAGE POLICY
Important note Even though this policy may indicate that a particular service or supply is considered covered, this conclusion is not necessarily based upon the terms of your particular benefit plan. Each
More informationMyeloablative versus Reduced Intensity Conditioning Regimen Cord Blood Transplants
Educational 2 Cord Blood Transplantation Myeloablative versus Reduced Intensity Conditioning Regimen Cord Blood Transplants William Arcese University of Rome Tor Vergata Rome Transplant Network 4th April
More informationChallenges of Hematopoietic Stem Cell Transplantation. Robert J. Soiffer, MD Dana Farber Cancer Institute
Challenges of Hematopoietic Stem Cell Transplantation Robert J. Soiffer, MD Dana Farber Cancer Institute Hematopoietic Stem Cell Transplantation Objectives Deliver sufficient chemo-radio therapy to destroy
More informationGRANIX (tbo-filgrastim)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils. A person with severe neutropenia has an absolute neutrophil
More informationBeyond Cell Dose: Selection of the Optimal Umbilical Cord Blood Unit. Karen Ballen, MD Massachusetts General Hospital June, 2012
Beyond Cell Dose: Selection of the Optimal Umbilical Cord Blood Unit Karen Ballen, MD Massachusetts General Hospital June, 2012 OUTLINE Cell Dose HLA Typing HLA C and KIR HLA Antibodies ABO and Racial/Ethnic
More informationSelecting an appropriately matched donor for hematopoietic
Transplant Outcomes in Acute Leukemia (I) Mary Eapen a and John E. Wagner b Umbilical cord blood (UCB) has gradually emerged over the last decade as an alternative source of hematopoietic cells for transplantation
More informationCord Blood: that other stem cell source. Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program
Cord Blood: that other stem cell source Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program CBMTG April 2012 The problem: In order to perform a BMT from one person to another one needs
More informationOUR JOURNEY THROUGH THE YEARS
The King Faisal Specialist Hospital and Research Centre Experience in Hematology, Oncology and Bone Marrow Transplantation OUR JOURNEY THROUGH THE YEARS REGGIE BELKHEDIM A Brief Overview: King Faisal Specialist
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description
More informationOutcome of Unrelated HSCT in Patients Lacking HLA Matched Related Donors: Iranian Stem Cell Donor Program (ISCDP)
Outcome of Unrelated HSCT in Patients Lacking HLA Matched Related Donors: Iranian Stem Cell Donor Program (ISCDP) October 18, 2014 19th Congress of APBMT, Hangzhou, China AMIR ALI HAMIDIEH, MD Iranian
More informationNorthside Hospital Blood & Marrow Transplant Program
Northside Hospital Blood & Marrow Transplant Program The Blood & Marrow Transplant roup O F G E O R G I A F O C U S O N T H E PAT I E N T S C O M PA S S I O N AT E C A R E S TAT E - O F - T H E - A R T
More informationUMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE
UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE HIND AL HUMAIDAN, MD,FRCPA Director, Blood Bank (Donor & Transfusion Services) and Stem Cell Cord Blood Bank Consultant Hematopathologist INTRODUCTION
More informationPhone: +44 20 8123 2220 Fax: +44 207 900 3970 office@marketpublishers.com http://marketpublishers.com
Global Stem Cell Umbilical Cord Blood (UCB) Market (Storage Service, Therapeutics, Application, Geography) - Size, Share, Global Trends, Analysis, Opportunities, Growth, Intelligence and Forecast, 2012-2020
More informationWhat we will discuss today
Umbilical cord blood banking It s Utility? Dr. Nita Radhakrishnan Pediatric Hematology Oncology Unit, Sir Ganga Ram Hospital, New Delhi What we will discuss today What are stem cells? What are the sources
More informationBlood and Marrow Stem Cell Transplantation
Blood and Marrow Stem Cell Transplantation Revised 2013 A Message from Louis J. DeGennaro, PhD President and CEO of The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society (LLS) is committed to
More informationA Cure for Sickle Cell Anemia and Thalassemia
IV Simpósio Internacional de Hemoglobinopatias A Cure for Sickle Cell Anemia and Thalassemia Bertram Lubin, MD and Mark Walters, MD 4 September 2007 Topics to be covered Cord blood: Importance and biology
More informationIn contrast to the very high transplant-related
Cord Blood: an Alternative Stem Cell Source or a New Standard? Juliet N. BARKER Memorial Sloan-Kettering Cancer Center, NY, ABD In contrast to the very high transplant-related mortality (TRM) associated
More informationReference: NHS England B04/P/a
Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation (HSCT) (All Ages): Revised Reference: NHS England B04/P/a 1 NHS England Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation
More informationStem Cell Transplantation in Adults
Recommendation Report Stem Cell Transplantation in Adults K. Imrie, R.B. Rumble, M. Crump, the Advisory Panel on Bone Marrow and Stem Cell Transplantation, and the Hematology Disease Site Group of Cancer
More informationStem Cell Transplantation in Severe Aplastic Anemia
Stem Cell Transplantation in Severe Aplastic Anemia Dr. D. Goodyear MD, FRCPC Division of Hematology and Hematological Malignancies, University of Calgary 1 of 11 Introduction Most cases of aplastic anemia
More informationOn April 4, a group of physicians at the 37th annual
By Ronale Tucker Rhodes, MS Better gene sampling and newer transplant regimens are making stem cell transplantation possible for a host of disease states that previously were rarely considered for this
More informationWhat is a Stem Cell Transplantation?
What is a Stem Cell Transplantation? Guest Expert: Stuart, MD Associate Professor, Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Drs. Ed and Ken. I am
More informationBone Marrow Transplant Update
Bone Marrow Transplant Update FALL 2012 WWW.SEATTLECCA.ORG/ADULT-BONE-MARROW-TRANSPLANT-NEWS.CFM Contact Us A transplant doctor from the Fred Hutchinson Blood and Marrow Transplant Program is available
More informationBone Marrow (Stem Cell) Transplant for Sickle Cell Disease
Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease 1 Produced by St. Jude Children s Research Hospital Departments of Hematology, Patient
More informationHow To Treat Multiple Myeloma With A Stem Cell Transplant
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy Versus Single Autologous Stem Cell Transplant Followed by Matched Sibling Nonmyeloablative Allogeneic
More informationNot All Stem Cells are the Same
Cord Blood Banking and Transplantation Jennifer Willert, M.D. Hematology/Oncology Blood and Marrow Transplant Rady Children s Hospital San Diego Clinical Professor UCSD Not All Stem Cells are the Same
More informationProgram Co-Chairmen: Dr. John Wagner, University of Minnesota Dr. Richard Champlin, M.D. Anderson Cancer Center
(last updated May 13, 2004) This is an activity offered by CBBS, a CMA accredited provider. Physicians attending this course may report up to 13.25 hours of Category 1 credits toward the California Medical
More informationTherapeutic Treatment Options: Chronic Blood Transfusions Bone Marrow Transplantation. Marianne E. McPherson Yee, MD, MSc
Therapeutic Treatment Options: Chronic Blood Transfusions Bone Marrow Transplantation Marianne E. McPherson Yee, MD, MSc Sickle Cell Treatment Options Supportive Care Newborn Screen PCN Immunizations Education
More informationCord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape
GENReports: Market & Tech Analysis Cord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape > Enal Razvi, Ph.D. Biotechnology Analyst, Managing Director SELECTBIO US enal@selectbio.us
More informationINFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002
INFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002 COVERAGE: SPECIAL COMMENT ON POLICY REVIEW: Due to the complexity of the Peripheral and Bone Marrow Stem Cell Transplantation
More informationTransplantation of cord blood stem cells from related or unrelated donors is considered investigational in all other situations.
MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Placental and Umbilical Cord Blood as a Source of Stem Cells
More informationCytoreductive Therapy for Autologous Cell Therapy in HIV
Cytoreductive Therapy for Autologous Cell Therapy in HIV Ronald Mitsuyasu, MD Professor of Medicine UCLA Center for Clinical AIDS Research and Education (CARE Center) HSC Transfer from CCR5-delta 32 Donor
More informationUmbilical Cord Blood Transplantation
Umbilical Cord Blood Transplantation V Rocha MD, PhD Hopital Saint Louis, Paris University 7 CIBMTR Milwaukee Umbilical Cord blood transplantation Background History Clinical results in children and adults
More informationCord Blood Biology and Transplantation
Cord Blood Biology and Transplantation Yossi Cohen MD MSc and Arnon Nagler MD Institute of Hematology, Department of Bone Marrow Transplantation and Cord Blood Bank, Sheba Medical Center, Tel Hashomer,
More informationLauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?
Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in
More informationEUROCORD. in 49 countries and 484 transplant centres* 264 EBMT 4847 (73%) cases 220 Non-EBMT 1797 (27%) cases
! 21%! EUROCORD 6756 cord blood transplantations performed from 1988 to March 2010 in 49 countries and 484 transplant centres* 264 EBMT 4847 (73%) cases 220 Non-EBMT 1797 (27%) cases * missing center
More informationTRANSPLANT BASICS Understanding transplant and how it works
TRANSPLANT BASICS Understanding transplant and how it works Thuy, transplant recipient AT EVERY STEP, WE ARE HERE TO HELP As you journey through transplant, you re not alone. Be The Match is ready to help.
More informationChapter 4 Section 23.1. High Dose Chemotherapy (HDC) And Stem Cell Transplantation
Surgery Chapter 4 Section 23.1 High Dose Chemotherapy (HDC) And Stem Cell Transplantation Issue Date: November 1, 1983 Authority: 32 CFR 199.4(e)(5) and (g)(15) 1.0 CPT 1 PROCEDURE CODES 38205, 38207,
More informationNational Survey of Blood and Marrow Transplant Center Personnel, Infrastructure and Models of Care Delivery
National Survey of Blood and Marrow Transplant Center Personnel, Infrastructure and Models of Care Delivery Report prepared by: Navneet S Majhail, MD, MS Lih-Wen Mau, PhD, MPH Tammy Payton Ellen M Denzen,
More informationObjectives. Cord Blood. Case 1. Case 1. Case 1. Case 1. To provide a framework for answering a family s questions about cord blood storage.
Cord Blood Should we save the baby s cord blood? Meghan A. Higman, MD, PhD Clinical Assistant Professor of Pediatrics Division of Pediatric Hematology/Oncology Assistant Professor of Oncology Pediatrics
More informationSESUG 2011 INTRODUCTION. Paper GH-12
Paper GH-12 Development of a SAS Macro for Automated Data Cleaning of Major Outcomes of Interest in Hematopoietic Cell Transplantation Peigang Li, Min Chen and Zhiwei Wang, CIBMTR, Milwaukee, WI ABSTRACT
More informationCorporate Medical Policy Cord Blood as a Source of Stem Cells
Corporate Medical Policy Cord Blood as a Source of Stem Cells File Name: Origination: Last CAP Review: Next CAP Review: Last Review cord_blood_as_a_source_of_stem_cells 2/2001 3/2015 3/2016 3/2015 Description
More informationJamie Peregrine, MD, PGY-4 KU-Wichita, OB/GYN Wesley Medical Center
Jamie Peregrine, MD, PGY-4 KU-Wichita, OB/GYN Wesley Medical Center Uses for umbilical cord stem cells Describe the indications and uses for umbilical cord stem cells. Counsel patients on the advantages
More informationThe donor search: the best donor or cord blood unit
The donor search: the best donor or cord blood unit Dr Bronwen Shaw Consultant in haematopoietic cell transplantation Royal Marsden Hospital /Anthony Nolan Overview Where do we find donors/units for transplantation
More informationHaematopoietic stem cell transplantation in Hong Kong
S C I E N T I F I C P A P E R Haematopoietic stem cell transplantation in Hong Kong Albert KW Lie WY Au Raymond Liang 李 國 維 區 永 仁 梁 憲 孫 The first case of haematopoietic stem cell transplant (HSCT) was
More informationBlood and Marrow Stem Cell Transplantation
Blood and Marrow Stem Cell Transplantation Printing of this publication made possible by an education grant from Table of Contents Introduction 2 Overview of Stem Cell Transplantation 3 Normal Blood and
More informationUnrelated donor umbilical cord blood transplantation for the treatment of hematologic malignancies Craig Sauter and Juliet N.
Unrelated donor umbilical cord blood transplantation for the treatment of hematologic malignancies Craig Sauter and Juliet N. Barker Adult Allogeneic Bone Marrow Transplantation Service, Memorial Sloan-Kettering
More informationTreatment of low-grade non-hodgkin lymphoma
Produced 28.02.2011 Due for revision 28.02.2013 Treatment of low-grade non-hodgkin lymphoma Lymphomas are described as low grade if the cells appear to be dividing slowly. There are several kinds of low-grade
More informationOutline of thesis and future perspectives.
Outline of thesis and future perspectives. This thesis is divided into two different sections. The B- section involves reviews and studies on B- cell non- Hodgkin lymphoma [NHL] and radioimmunotherapy
More informationState-of-the-Art Treatment for Lymphoma December 19, 2007 Guests: David Maloney, M.D., Ph.D Hosted by Andrew Schorr INTRODUCTION
State-of-the-Art Treatment for Lymphoma December 19, 2007 Guests: David Maloney, M.D., Ph.D Hosted by Andrew Schorr Please remember the opinions expressed on Patient Power are not necessarily the views
More informationOne-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers
The new england journal of medicine Original Article One-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers John E. Wagner, Jr., M.D., Mary Eapen, M.B., B.S., Shelly Carter, D.Sc.,
More informationBone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris
Bone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris Background Hematopoietic stem cell transplantation (HSCT) is
More informationNot for publication or presentation
MINUTES CIBMTR WORKING COMMITTEE FOR GVHD Orlando, Florida Thursday, February 25, 2010, 2:45 pm 4:45 pm Statisticians: Scientific Directors: Steven Pavletic MD, National Cancer Institute Telephone: 301-402-4899;
More informationMore transplant success.
More stem cells. More transplant success. ViaCord has the highest published transplant success rates. 2,9a FOR CURRENT Treatments * - All transplant recipients were conditioned with chemotherapy/radiation
More informationREPORT NUMBER 17. Transplantation of Allogeneic Hematopoietic Stem Cells from Unrelated Donors in Adult Patients at the MUHC
REPORT NUMBER 17 Transplantation of Allogeneic Hematopoietic Stem Cells from Unrelated Donors in Adult Patients at the MUHC This analysis was prepared for the Technology Assessment Unit (TAU) of the McGill
More informationStem Cell Background Paper
Stem Cell Background Paper Introduction...2 Stem Cell Basics...3 Stem Cell Process Flow...9 Comparison of Blood, Stem Cells, Tissues and Organs Processes...10 Responsibilities for the Blood, Stem Cells,
More informationPlacental and Umbilical Cord Blood as a Source of Stem Cells
Placental and Umbilical Cord Blood as a Source of Stem Cells Policy Number: 7.01.50 Last Review: 12/2015 Origination: 12/2001 Next Review: 12/2016 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationPlacental and Umbilical Cord Blood as a Source of Stem Cells
Placental and Umbilical Cord Blood as a Source of Stem Cells Policy Number: 7.01.50 Last Review: 12/2014 Origination: 12/2001 Next Review: 12/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue
More information10 th Annual International Cord Blood Transplantation Symposium June 7-9, 2012 Preliminary Scientific Program. Thursday, June 7
10 th Annual International Cord Blood Transplantation Symposium June 7-9, 2012 Preliminary Scientific Program Thursday, June 7 7:00 8:00 AM Breakfast in Exhibit Hall Session IA 8:00 10:00 AM Advances in
More informationBlood & Marrow Transplant Glossary. Pediatric Blood and Marrow Transplant Program Patient Guide
Blood & Marrow Transplant Glossary Pediatric Blood and Marrow Transplant Program Patient Guide Glossary Absolute Neutrophil Count (ANC) -- Also called "absolute granulocyte count" amount of white blood
More informationClinical Commissioning Policy: Haematopoietic Stem Cell Transplantation. April 2013. Reference: NHSCB/B04/P/a
Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation April 2013 Reference: NHS Commissioning Board Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation First published:
More information4. All cord blood banks should be subject to the same standards, regulations and accreditation requirements.
WMDA Policy Statement on the Utility of Autologous or Family Cord Blood Unit Storage The WMDA Board adopted this policy on 25 th of May 2006. Policy updated _April 2011 The Cord Blood Working Group and
More informationHow To Save A Patient From A Cancer
BIOSTATISTICS FOR TRANSLATIONAL & CLINICAL RESEARCH Blood-&-Marrow Transplants & CANCERS Stem Cells Stem cells are immature body cells that act like "starter dough" because they can make identical copies
More informationBlood and Marrow Stem Cell Transplantation LEUKEMIA LYMPHOMA MYELOMA
Blood and Marrow Stem Cell Transplantation LEUKEMIA LYMPHOMA MYELOMA Table of Contents Introduction 1 Here to Help 2 Normal Blood and Marrow 4 Overview and Types of Stem Cell Transplantation 6 Stem Cell
More informationPT CordLife Indonesia Premium Cordblood Bank. PT CordLife Indonesia Premium Cordblood Bank
Cordblood Stem Cells and The Role of Cordblood Bank in Supporting Stem Cells Research Presentation Overview Company profile Haematopoietic stem cells in cordblood What we can do to help 1 2 PT CordLife
More informationNews. The Blood and Marrow Transplant Program at Northside Hospital. New Clinical Trial Assesses Use of CTLA-4 Blockade with Ipilimumab IN THIS ISSUE:
IN THIS ISSUE: Winter 2014 www.bmtga.com www.northside.com The Blood and Marrow Transplant Program at Northside Hospital News New Clinical Trial Assesses Use of Ipilimumab Page 1 NSH-BMT, Leukemia & Lymphoma
More informationProgress Report JANUARY DECEMBER. Sharing Knowledge. Sharing Hope.
Progress Report JANUARY DECEMBER 2014 Sharing Knowledge. Sharing Hope. CIBMTR (Center for International Blood and Marrow Transplant Research ) is a research collaboration between the National Marrow Donor
More informationGraft Failure After HSCT
Graft Failure After HSCT Vanderson Rocha, MD, PhD Professor of Haematology- Oxford University Bone Marrow Transplant Unit- Sirio Libanes Hospital- Sao Paulo Scientific Director of Eurocord-Paris Clinical
More informationThe Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma
The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma 11 th Annual National Leadership Summit on Health Disparities Innovation Towards Reducing Disparities Congressional Black
More informationP R E S S K I T 2013 TABLE OF CONTENTS. About the European Group for Blood and Marrow Transplantation
TABLE OF CONTENTS About the European Group for Blood and Marrow Transplantation Haematopoietic Stem Cell Transplantation (HSCT): Key facts & figures EBMT Data - A foundation for cutting-edge research Clinical
More information5. All cord blood banks should be subject to the same standards, regulations and accreditation requirements.
WMDA Policy Statement for the Utility of Autologous or Family Cord Blood Unit Storage (This policy statement has been approved and adopted by the WMDA board on the 25 th of May 2006) The Cord Blood Registries
More informationBone Marrow Transplant Services in New Zealand for Adults
Bone Marrow Transplant Services in New Zealand for Adults Citation: Ministry of Health. 2011. Bone Marrow Transplant Services in New Zealand for Adults Service Improvement Plan. Wellington: Ministry of
More informationSummary of Advisory Council on Blood Stem Cell Transplantation: Recommendations and Status
of Advisory Council on Blood Stem Cell Transplantation: Recommendations and Shelley Grant Branch Chief, Blood Stem Cell Transplantation Program September 11, 2015 Overview December 20, 2005 - HRSA began
More informationClinical Outcomes of Unrelated Donor Umbilical Cord Blood Transplantation for 30 Adults with Hematological Malignancies
Clinical Outcomes of Unrelated Donor Umbilical Cord Blood Transplantation for 30 Adults with Hematological Malignancies KOICHIRO KOBAYASHI 1, YOSHINOBU MAEDA 1, YOSHITAKA HARA 1, MIYUKI NISHIE-KATAOKA
More informationGlobal Stem Cell Umbilical Cord Blood
Report Code: DI 14114 Global Stem Cell Umbilical Cord Blood (product Types, Application, Technology, End Users and Geography) Global Share, Size, Industry Analysis, Trends, Opportunities, Growth and Forecast,
More information